Fukang Pharmaceutical recently announced the completion of the B round of financing. This round of financing is participated by listed companies and investment institutions such as the equity investment fund of Jointown Pharmaceutical Group Co., Ltd. and Shaoxing Shangyu Hangzhou Bay Economic Development Zone Holding Group. The financing is mainly used to accelerate the global commercialization of the company’s first product that is about to be approved process and the global development process of the company’s multiple innovative drug pipelines.
According to public information, Fukang Pharmaceuticals is a new drug research and development enterprise in the clinical stage based in China and facing the world, and is committed to developing innovative drugs in the field of tumor diseases. Guided by the unmet clinical drug needs in China and the world, the company designs and develops original new drugs with “First-in-Class” or “Best-in-Class” potential, deploys a new generation of bispecific antibody biological drugs and differentiated small Molecular drugs provide innovative treatment options for tumor patients.
Dr. Shen Xiaokun, CEO of Fukang Pharmaceuticals, said: “We are very honored to have the trust and strong support of Jointown Pharmaceutical Group and new and old shareholders. In the process of commercialization, the company will speed up the process of listing and registration in regions outside Greater China. Currently, there are a number of business partners under negotiation. This year, Prokang Pharmaceuticals acquired the world’s only clinical-stage PI3Kβ/δ dual drug from Karus Therapeutics in the UK. Highly selective inhibitors have completed production transfer and submitted applications for orphan drug indications to the FDA, and are advancing the development of global registration clinical trials. Fukang Pharmaceuticals adheres to the globalization route, and currently all products under research have global intellectual property rights. On the other hand, the company is also speeding up the construction of an innovative technology platform for AI new drug research and development, and has joined forces with many AI companies such as Shenshi Technology to continuously explore new technologies and methods. With the continuous support of many excellent investment institutions and banks, We are confident that we will advance the various clinical trials of the company’s new drugs at home and abroad at full speed, accelerate the research and development process of new drugs, and benefit patients around the world as soon as possible.”
Dr. Yu Zuoping, head of the Venture Capital Division of Jointown Group and general manager of Jointown Ventures, said: “We are very pleased to help the rapid development of Fukang Pharmaceutical’s global innovative drug research and development. Fukang Pharmaceutical has a very good product pipeline and Huge commercialization prospects. The Right-6D new drug research and development strategy of Fukang Pharmaceuticals aims at the huge unmet clinical needs, and has brought innovative treatment options to patients with cholangiocarcinoma and pancreatic cancer. Currently, the three new drugs in the clinical stage all have With obvious differences and advantages, two products will enter the clinical stage next year. The company is about to enter the commercialization stage and is expected to achieve hundreds of millions of sales revenue. We are very optimistic about the company’s future development. Jointown Pharmaceutical Group hopes to become an important strategy for Fukang Partners, fully support Fukang Pharmaceutical’s continuous breakthroughs and innovations, and jointly benefit patients around the world.”
media reports
Venture State Investment Circle Sina
This article is transferred from: https://readhub.cn/topic/8mitxd9t71g
This site is only for collection, and the copyright belongs to the original author.